Brown tumor complicating end-stage kidney disease
- 1 January 2020
- journal article
- research article
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology – Case Studies
- Vol. 8 (01) , 72-79
Abstract
Longstanding, severe hyperparathyroidism (HPT) can lead to the formation of “brown tumors”. A brown tumor is a radiolucent bone lesion that is locally destructive; it is not a neoplasm, but rather a stromal mass consisting of fibrous tissue, poorly mineralized woven bone, and supporting vasculature. These tumors are a rare complication of advanced primary or secondary HPT. We present a young female with chronic kidney disease (CKD) on hemodialysis with uncontrolled secondary HPT (SHPT). The patient presented with progressive lower extremity weakness and back pain. CT imaging showed multiple lytic bone lesions involving several ribs and the spine. Subsequent MRI imaging of the thoracic and lumbar spine confirmed expansile bone lesions consistent with brown tumors. One mass protruded into the spinal canal causing severe stenosis at T3 with underlying cord edema. The other lesion at T12 caused only moderate spinal canal stenosis. Our patient underwent urgent neurosurgical resection of the tumor at T3 followed by subtotal parathyroidectomy (PTX).Keywords
This publication has 26 references indexed in Scilit:
- Phosphate Toxicity in CKD: The Killer among UsClinical Journal of the American Society of Nephrology, 2016
- MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and managementEuropean Journal of Endocrinology, 2015
- Secondary HyperparathyroidismClinical Journal of the American Society of Nephrology, 2011
- Brown tumor of the cervical spine: a case report and review of the literatureClinical Rheumatology, 2010
- Forging Forward with 10 Burning Questions on FGF23 in Kidney DiseaseJournal of the American Society of Nephrology, 2010
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006
- Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International, 2006
- FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 2004
- K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.2003
- Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1α,25-Dihydroxyvitamin D3 ProductionJournal of Biological Chemistry, 2003